妊娠期霍奇金淋巴瘤患者的产科与母体结局:多中心回顾性队列研究
该多中心回顾性队列研究纳入1969年至2018年17个中心134例妊娠期确诊霍奇金淋巴瘤患者,分析产科结局、孕期管理及母体生存。结果显示孕期化疗暴露增加产科并发症但母体生存与非妊娠匹配患者无差异,提示可在密切产科监测下考虑孕期化疗或产后治疗。
要点
- 孕期化疗暴露组产科并发症更多,以早产宫缩和胎膜早破常见。
- 化疗暴露新生儿出生体重百分位较低,但小于胎龄儿和NICU入住率无差异。
- 妊娠期霍奇金淋巴瘤患者母体生存与非妊娠匹配对照无显著差异。
核心结论
- 接受孕期治疗的霍奇金淋巴瘤患者早产宫缩或胎膜早破发生率高于未孕期治疗者。
- 妊娠期霍奇金淋巴瘤患者与非妊娠匹配患者的母体生存无差异。
- 在选定患者中可考虑孕期化疗或推迟至产后,并定期产科随访以保障胎儿生长。
研究设计与样本
- 多中心回顾性队列研究,纳入1969年1月1日至2018年8月1日17个学术中心的134例妊娠期确诊霍奇金淋巴瘤患者。
- 按三个时段(1995年前、1995-2004年、2005-18年)分析患者管理。
- 母体生存分析比较77例妊娠患者与211例非妊娠匹配对照(按分期和预后评分匹配),所有生存分析患者自1997年1月1日起接受标准ABVD方案。
主要发现
- 134例中72例(54%)在孕期开始化疗,56例(42%)孕期未治疗,6例(4%)仅接受放疗。
- 化疗暴露新生儿NICU入住率为29%(19/69),非暴露为35%(12/42)。
临床怎么用
- 妊娠期霍奇金淋巴瘤患者可考虑孕期化疗或推迟至产后,需结合分期和患者意愿个体化决策。
- 孕期治疗期间应定期产科随访,关注早产宫缩和胎膜早破等并发症。
- 新生儿需监测出生体重百分位,但小于胎龄儿和NICU入住率未见显著增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcomes for mother and child following a diagnosis of Hodgkin lymphoma during pregnancy are underinvestigated, and antenatal management of the disease has not been reported on widely. The aim of this study was to assess obstetric outcomes, antenatal management, and maternal survival in patients with Hodgkin lymphoma diagnosed during pregnancy who were registered in the International Network on Cancer, Infertility and Pregnancy (INCIP) database. METHODS: We did a multicentre, retrospective cohort study including oncological and obstetric data from 134 pregnant patients diagnosed with Hodgkin lymphoma between Jan 1, 1969, and Aug 1, 2018. Data collected from the INCIP database were obtained from 17 academic centres in Belgium, Czech Republic, Denmark, Greece, Israel, Italy, Mexico, the Netherlands, Russia, the UK, and the USA. We analysed patients' management over three epochs (before 1995, 1995-2004, and 2005-18). Obstetric outcomes (birthweight, obstetric or neonatal complications, and admission to a neonatal intensive care unit [NICU]) of patients who received antenatal chemotherapy were compared to those of patients who did not receive antenatal treatment. Maternal progression-free and overall survival was assessed by disease stage at diagnosis in pregnant patients and compared with outcomes of non-pregnant patients with Hodgkin lymphoma selected from databases of three tertiary centres, matched for stage and prognostic score. All patients included in survival analyses received standard doxorubicin, bleomycin, vinblastine and dacarbazone (ABVD) therapy since Jan 1, 1997. FINDINGS: Of the 134 pregnant patients diagnosed with Hodgkin lymphoma during pregnancy. 72 (54%) patients initiated antenatal chemotherapy, 56 (42%) did not receive treatment during pregnancy, and 6 (4%) received only radiotherapy. Over the years, chemotherapy was increasingly commenced during pregnancy. The incidence of neonates who were small for gestational age did not differ between chemotherapy-exposed neonates (15 [22%] of 69) and non-exposed neonates (six [16%] of 42; p=0·455). Admission to NICU also did not differ between groups (19 [29%] exposed to antenatal chemotherapy vs 12 [35%] unexposed to antenatal chemotherapy). Birthweight percentiles were lower in neonates prenatally exposed to chemotherapy compared with non-exposed neonates (p=0·035). Patients receiving antenatal therapy had more obstetric complications than those without antenatal therapy (p=0·005), the most common complications being preterm contractions (nine [12%] vs three [7%]) and preterm rupture of membranes (four [5%] vs 0). For the maternal survival analyses, we compared 77 pregnant patients and 211 non-pregnant, matched controls. 5-year progression-free survival for patients with early-stage Hodgkin lymphoma was 82·6% (95% CI 67·4-91·1) for 62 pregnant patients and 88·3% (81·6-92·7) for 142 controls (hazard ratio [HR] 1·80, 95% CI 0·84-3·87; p=0·130; 5-year overall survival was 97·3% (82·3-99·6) and 98·4% (93·6-99·6; HR 1·63, 0·35-7·65; p=0·534). In patients with advanced-stage disease (15 pregnant patients and 69 non-pregnant controls), 5-year progression-free survival was 90·9% (95% CI 50·8-98·7) versus 74·0% (60·9-83·3); HR 0·36, 95% CI 0·04-2·90; p=0·334. 5-year overall survival was 100% (no events occurred) and 96·2% (95% CI 85·5-99·1; HR cannot be estimated; p=0·146). INTERPRETATION: Occurrence of preterm contractions or preterm rupture of membranes was higher in patients with Hodgkin lymphoma receiving antenatal treatment compared with those who did not initiate treatment during pregnancy. Maternal survival did not differ between pregnant and non-pregnant patients with Hodgkin lymphoma, suggesting that antenatal chemotherapy or deferral of treatment until postpartum in selected patients can be considered, with regular obstetric follow-up to safeguard foetal growth. FUNDING: European Research Council, Research foundation Flanders, and Charles University Ministry of Health of the Czech Republic.
引用
- Maggen C, Dierickx D, Lugtenburg P, et al. Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. Lancet Haematol. 2019. PMID: 31564649. doi:10.1016/S2352-3026(19)30195-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。